GSK3882347 / GSK - LARVOL DELTA

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1 | N=140 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed

Trial completion • Infectious Disease • Nephrology

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years (clinicaltrials.gov) - P1 | N=27 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed

Trial completion • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: GlaxoSmithKline | Suspended ➔ Recruiting | Phase classification: P1b ➔ P1 | N=80 ➔ 122 | Trial completion date: Jul 2024 ➔ Feb 2025 | Trial primary completion date: Jul 2024 ➔ Jan 2025

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: GlaxoSmithKline | Suspended ➔ Recruiting | Trial completion date: Aug 2023 ➔ Oct 2024 | Trial primary completion date: Aug 2023 ➔ Sep 2024

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

C-mannoside FimH antagonists as oral therapeutics for urinary tract infections (ACS-Sp 2024) - "In mouse models of UTI, lead compounds showed robust efficacy at reducing bacterial burdens when dosed as low as 0.5 mg/kg. These efforts have led to the identification and selection of clinical candidate, GSK3882347, currently being evaluated in Phase 1b clinical trials as a novel, antibiotic-sparing treatment for acute UTI."

Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Suspended | Sponsor: GlaxoSmithKline | Trial completion date: Dec 2023 ➔ Jul 2024 | Trial primary completion date: Dec 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years (clinicaltrials.gov) - P1 | N=30 | Suspended | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Suspended

Trial suspension • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Suspended | Sponsor: GlaxoSmithKline | Recruiting ➔ Suspended

Trial suspension • Infectious Disease • Nephrology

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Not yet recruiting | Sponsor: GlaxoSmithKline | Initiation date: Dec 2021 ➔ Mar 2022

Trial initiation date • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b; N=80; Not yet recruiting; Sponsor: GlaxoSmithKline

Clinical • New P1 trial • Infectious Disease • Nephrology

Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants. (clinicaltrials.gov) - P1; N=61; Completed; Sponsor: GlaxoSmithKline; Recruiting ➔ Completed

Trial completion • Infectious Disease • Nephrology